Dongwha Pharm
동화약품 · 000020
Health Care Pharmaceuticals · KOSPI
Market cap US$110.7M (₩152.8B)
Overview
Dongwha Pharm makes prescription and over-the-counter medicines, medical devices, and distributes pharmaceutical products to hospitals, pharmacies, and other healthcare buyers across South Korea and overseas.
Listed on KOSPI, South Korea's main stock exchange, it operates through several business lines: a core pharmaceuticals division, a medical-device manufacturing subsidiary, a pharmaceutical distribution chain, and a small financial services unit. Pharmaceuticals account for the largest share of its consolidated revenue, with medical-device manufacturing and drug distribution making up most of the remainder.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$261.7M
- FY2024US$336.9M
- FY2025US$359.7M
Operating profit
- FY2023US$13.6M
- FY2024US$9.7M
- FY2025US$186.1K
Net income
- FY2023US$20.5M
- FY2024US$1.6M
- FY2025US$2.8M
Key ratios (FY2025)
Why it matters
Its medical-device subsidiary, Medissey, applies interdisciplinary engineering, combining clinical medicine with electrical, mechanical, materials, and optical technologies, to design and manufacture its products.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?